Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Benefit of Local Anesthesia at the Sternum in Patients With Coronary Surgery (PARA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03734159
Recruitment Status : Completed
First Posted : November 7, 2018
Last Update Posted : July 7, 2020
Sponsor:
Information provided by (Responsible Party):
CMC Ambroise Paré

Tracking Information
First Submitted Date  ICMJE November 5, 2018
First Posted Date  ICMJE November 7, 2018
Last Update Posted Date July 7, 2020
Actual Study Start Date  ICMJE December 13, 2018
Actual Primary Completion Date June 21, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 6, 2018)
Show that the preoperative realization of a parasternal block limites the posology of remifentanil administered during sternotomies to maintain blood pressure and heart rate within recommended ranges [ Time Frame: Intraoperative period : from intubation to sternal retractor setup ]
Maximal dose of remifentanil (morphine peak) required to maintain hemodynamic parameters (arterial blood pressure and heart rate) in the appropriate values during intubation, skin incision, sternotomy and sternal retractor setup
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 3, 2020)
  • Hemodynamic response : heart rate [ Time Frame: Intraoperative period : from the start of general anesthesia maintenance to the fifth minute after sternal retractor setup ]
    Measure of heart rate in bpm
  • Hemodynamic response : arterial blood pressure [ Time Frame: Intraoperative period : from the start of general anesthesia maintenance to the fifth minute after sternal retractor setup ]
    Measure of diastolic and systolic arterial blood pressure in mmHg
  • Hemodynamic response : patient state index [ Time Frame: Intraoperative period : from the start of general anesthesia maintenance to the fifth minute after sternal retractor setup ]
    Measure of patient state index ranging from 0 to 100 (0=very deep anesthesia, 100=no hypnotic state)
  • Dose of hypnotic drug [ Time Frame: Intraoperative period : from induction of anesthesia to skin closure ]
    Total amount of propofol administered during surgery
  • Dose of analgesic drug [ Time Frame: Intraoperative period : from induction of anesthesia to skin closure ]
    Total amount of remifentanil administered during surgery
  • Inflammatory response [ Time Frame: 7 days ]
    Serum concentrations of cytokines in pg/ml (composite : pro- (IL-6, IL-8, IL-1β, TNF-α, IFN-γ) and anti-inflammatory (IL-10) cytokines)
  • Pain level during extubation: Numeric scale [ Time Frame: 8 hours ]
    Numeric scale of pain, ranging from 0 to 10 (0 = no pain, 10= worst possible pain)
  • Complications [ Time Frame: 7 days ]
    Incidence of acute respiratory distress syndrome, pneumopathy, kidney failure or hypertension
Original Secondary Outcome Measures  ICMJE
 (submitted: November 6, 2018)
  • Hemodynamic response : heart rate [ Time Frame: Intraoperative period : from the start of general anesthesia maintenance to the fifth minute after sternal retractor setup ]
    Measure of heart rate in bpm
  • Hemodynamic response : arterial blood pressure [ Time Frame: Intraoperative period : from the start of general anesthesia maintenance to the fifth minute after sternal retractor setup ]
    Measure of diastolic and systolic arterial blood pressure in mmHg
  • Dose of hypnotic drug [ Time Frame: Intraoperative period : from induction of anesthesia to skin closure ]
    Total amount of propofol administered during surgery
  • Dose of analgesic drug [ Time Frame: Intraoperative period : from induction of anesthesia to skin closure ]
    Total amount of remifentanil administered during surgery
  • Inflammatory response [ Time Frame: 7 days ]
    Serum concentrations of cytokines in pg/ml (composite : pro- (IL-6, IL-8, IL-1β, TNF-α, IFN-γ) and anti-inflammatory (IL-10) cytokines)
  • Pain level during extubation: Numeric scale [ Time Frame: 8 hours ]
    Numeric scale of pain, ranging from 0 to 10 (0 = no pain, 10= worst possible pain)
  • Complications [ Time Frame: 7 days ]
    Incidence of acute respiratory distress syndrome, pneumopathy, kidney failure or hypertension
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE The Benefit of Local Anesthesia at the Sternum in Patients With Coronary Surgery
Official Title  ICMJE Interest of Parasternal Block to Limit the Doses of Anesthetics Necessary for the Maintenance of Arterial Blood Pressure and Heart Rate in the Recommended Values During Sternotomy in Patients Undergoing Coronary Artery Bypass Graft
Brief Summary

Patients undergoing coronary artery bypass grafting are at risk for perioperative myocardial ischemia. Episodes of tachycardia and hypertension, which are associated with an increase in myocardial oxygen consumption, are predictive events of these ischemia.

During cardiac surgery by sternotomy, some maneuvers, e.g. intubation, skin incision, sternotomy and cannulation, may be associated with tachycardia and/or increases in blood pressure despite an adequate level of anesthesia. Usually these episodes are controlled by the administration of a high-dose of anesthetic agents.

The parasternal block, by bolus or continuous infusion through a single catheter, showed its effectiveness on postoperative pain after sternotomy. It allows a blocking of anterior branches of intercostal nerves at the lateral edge of the sternum; branches in charge of innervation of the sternum and the overlying skin surface.

The preoperative parasternal block, once general anesthesia performed, could provide an effective level of locoregional anesthesia of the chest wall, thus limiting the occurrence of episodes of tachycardia and / or hypertension without having to resort to massive doses of anesthetic agents during sternotomy in patients undergoing coronary bypass surgery.

Detailed Description

This randomized double blinded placebo-controlled clinical trial will include patients undergoing coronary artery bypass grafting.

Locoregional anesthesia of the chest wall will be performed under ultrasound, once general anesthesia performed. A total volume of 60 ml of sodium chloride 0.9% (placebo group) or ropivacaine 0.25% (experimental group) divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5) will be injected.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Condition  ICMJE Coronary Bypass Graft Stenosis
Intervention  ICMJE
  • Drug: Ropivacaine
    Injection of 60 ml of ropivacaine 0.25% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
  • Drug: sodium chloride 0.9%
    Injection of 60 ml of sodium chloride 0.9% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
Study Arms  ICMJE
  • Experimental: parasternal block
    preoperative parasternal block by ropivacaine injection
    Intervention: Drug: Ropivacaine
  • Placebo Comparator: physiological serum
    sodium chloride injection
    Intervention: Drug: sodium chloride 0.9%
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 29, 2019)
35
Original Estimated Enrollment  ICMJE
 (submitted: November 6, 2018)
30
Actual Study Completion Date  ICMJE November 7, 2019
Actual Primary Completion Date June 21, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients undergoing coronary artery bypass graft requiring sternotomy other than re-interventions and combined surgeries
  • Consent for participation
  • Affiliation to the french social security system

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Patients under protection of the adults (guardianship, curator or safeguard of justice)
  • Communication difficulties or neuropsychiatric disorder
  • Neuropathic disease
  • Constitutional coagulation disorders
  • Kidney insufficiency
  • Sensitivity to nonsteroidal anti-inflammatory drugs
  • Hypersensitivity to local anaesthetics
  • Chronic use of opioid analgesics
  • Corticosteroid treatment or immunosuppressive therapy
  • Autoimmune disease
  • Chronic pain syndrome or fibromyalgia
  • Emergency cardiac surgery
  • Hypovolemia
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03734159
Other Study ID Numbers  ICMJE 2018/07
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party CMC Ambroise Paré
Study Sponsor  ICMJE CMC Ambroise Paré
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Sébastien Bloc, MD CMC Ambroise Paré
PRS Account CMC Ambroise Paré
Verification Date December 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP